Overview

SNC115 Injections in Patients With Recurrent/Refractory Small Cell Lung Cancer and Lung Large Cell Neuroendocrine Carcinoma

Status:
RECRUITING

Trial end date:
2025-12-30

Target enrollment:

Participant gender:

Summary

This study is a FIH dose escalation clinical study, with single arm, open label and design, in order to observe the preliminary safety and Pharmacokinetic of SNC115 Injection in participants with Recurrent/refractory small cell lung cancer and Lung large cell neuroendocrine carcinoma.

Phase:

PHASE1

Details

Lead Sponsor:

Shanghai Simnova Biotechnology Co.,Ltd.

Collaborator:

Shanghai Chest Hospital